INS and Hypoglycemia: Incretins, such as glucagon-like peptide-1 (GLP-1) analogues and GLP-1/DPP4-peptidase inhibitors, can increase meal-related insulin secretion without increasing risk for hypoglycemia, and are useful for diminishing hyperglycemia.